NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Centivax, Inc.

Centivax, Inc.

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.centivax.com/

Last Round

VC Round

Mar 30, 2026

Total Funding Raised

$79.99M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Centivax, Inc. is a biotechnology company that deploys a proprietary computational immune-engineering platform to create universal vaccines and therapies for infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2G

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

universal vaccinebiotechnologycomputational immunologyvaccine platformpandemic preparednessdrug discoverybiodefenseclinical trialsepitope focusingAI drug discoveryin silico vaccine designinfectious disease preventionB2Gtherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Centivax, Inc. Comps

Public and private peers based on sector, stage, and business model.

Centivax, Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Centivax, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 30, 2026
GrantJul 8, 2025
Series AJul 8, 2025
SeedNov 16, 2022
GrantNov 1, 2019

Key People

Founding team and executive leadership

Sawsan Youssef

Chief Science Officer (CSO)-Co-Founder

Founding Team

Stephanie Wisner

Co-Founder, Treasurer, Chief Business Officer

Founding Team

Jacob Glanville

Founder, CEO President

Founding Team

Nicholas Bayless

Chief Technology Officer

Executive Team

Centivax, Inc. Investors

Notable investors and investment history

Centivax, Inc. investors
InvestorRounds
Kendall Capital PartnersSeries A, VC Round
NFXSeries A, Seed
Future VenturesSeries A
CEPIGrant
NIH RADxGrant
The Bill & Melinda Gates Foundation TrustGrant
Base4 CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 30, 2026

    $37M raised in early funding round.

  • Mar 30, 2026

    Developing a next-generation universal vaccine platform with support from Meiji Seika Pharma.

Centivax, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Centivax, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Centivax, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range36
Year Founded2019
Last FundingMar 30, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.